TrialInflammatory bowel diseases2022

Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.

Geert R D'Haens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.